Gilead Sciences Story Overview

GILD -- USA Stock  

USD 75.62  2.35  3.21%

Macroaxis News
  
By David Taylor

Gilead Sciences made a $10 billion bet and lost.  They invested heavily into a drug that was denied release by the FDA.  Naturally, the stock was sold off sharply.  While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.  But, just because the stock is beaten down as it is, does that mean it is a bad bet?

 

Pharmaceutical Products
Fama & French Classification
Gilead Science may be poised to see its stock price higher for a few reasons.

Gilead Science took a bad hit when their bet on a medical trial failed.  Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead.  Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio.  For that matter, by any matrix, the stock is cheap and should go higher.  




Gilead Sciences made a $10 billion bet and lost.  They invested heavily into a drug that was denied release by the FDA.  Naturally, the stock was sold off sharply.  While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.  But, just because the stock is beaten down as it is, does that mean it is a bad bet?

The first thing you see when you start to evaluate an investment into the company is the matrix of its valuation.  Pick anything, with either its stock price to free cash flow ratio, stock price to earnings ratio or stock price to sales ratio and the stock is dirt cheap.  But, just because a company’s stock is dirt cheap, does that necessarily mean the company’s stock will necessarily go higher?

First, the stock is trading at $75.00 per share.  Here are the earnings for the company:

2011:    $1.81

2012:    $1.71  

2013:    $2.01 

2014:    $7.95  

2015:  $12.37 

The company’s stock is trading at a variable of 6-times earnings.  That is incredibly low considering the earnings that it does have.  However, I will acknowledge the problems that this company had with its failed drug trials, and the subsequent sell-off of the stock from $125.00 all the way down to $75.00.  Fortunately, so does the company itself.  

The company acknowledges that future growth may be difficult with two of its best-selling drugs for Hepatitis-C and HIV.  The company is actively seeking out growth from acquisitions and has already jumped in to purchase some other companies.  But, buying growth usually comes at a  price, and that price is debt-servicing.  The company has taken on more debt.  But, in that process it has not pushed its ratio for debt-to-assets, and, in fact the assets have multiplied by a factor of 3 over the past 5 years.  

Since its debt-to-assets ratio is still very manageable, the company can grow from this point and begin to work towards acquiring more companies to grow.  Gilead is sitting on a great deal of cash.  So, the company has the ability to acquire without taking on any more debt from this point forward.  That is a huge advantage considering they are a company that is looking to expand its growth through acquisition.  

The real thing that I see in this company is the price of the stock.  Gilead, despite trading at $75.00 per share, it is ultra-cheap.  This is the entire point of what I like about this company.  They have the cash that I mentioned.  They have a great deal of revenue.  They are profitable.  And they are cheap.  They are ripe for being acquired.  It is not too far of a reach to see another drug maker to pick this company up propping up the price of the stock instantly.  The company’s stock should easily be trading at 15 times earnings.  That is twice the price right now.  Given that variable, I see the market correcting itself and coming more in line with the potential that this company offers.  

The beauty of the stock market is that there are individuals out there that look for potential investments into companies like this.  These individuals whole role is to make sure there is price continuity.  Because of that I see this stock’s price correcting itself over the course of the next year, trading at a price to earnings ratio more akin to the average market.  That means a potential large move upward in the stock.  That is what makes this stock such a great buy. 

Story Momentum

This media report from Macroaxis distributed on January 10, 2017 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.65% . The overall trading delta when the story was published against the current closing price is 1.12% .

Similar stores for Gilead Sciences

a day ago at http://nasdaqclick.com 
Analysts Noticeable BuzzersGilead Sciences, Inc.
nasdaq News
Nasdaq Click Full coverage
few days ago at www.macroaxis.com 
Payment of 894 shares by Metza Kristen of Gilead Sciences subject to Rule 16b-3
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. Payment of exercise price or tax liability by delivering or withholding securities
over a week ago at www.macroaxis.com 
Exercise or conversion by Kevin Young of 20000 shares of Gilead Sciences subject to Rule 16b-3
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at www.macroaxis.com 
Sale by John Martin of 9800 shares of Gilead Sciences
Macroaxis News
Filed transaction by Gilead Sciences Inc director. General open market or private sale of non-derivative or derivative security
over two weeks ago at www.macroaxis.com 
Sale by Gregg Alton of 100 shares of Gilead Sciences
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. General open market or private sale of non-derivative or derivative security
over two weeks ago at http://www.bloomberg.com 
Cancer Startups Bold IPO Target Carries Management Premium
bloomberg News
BloombergFull coverage
over two weeks ago at www.macroaxis.com 
Sale by Nicholas Moore of 200 shares of Gilead Sciences
Macroaxis News
Filed transaction by Gilead Sciences Inc director. General open market or private sale of non-derivative or derivative security
over three weeks ago at http://postanalyst.com 
Blackrock Inc. is the biggest holder of Gilead Sciences, Inc.
news
Post AnalystMagnetizing Stocks Gilead Sciences, Inc. , Zillow Group, Inc. , Splunk Inc. The Stock Street You dont want to miss the boat Gilead Sciences, Inc. FinBulletinFull coverage
over three weeks ago at www.macroaxis.com 
Sale by John Milligan of 2000 shares of Gilead Sciences
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. General open market or private sale of non-derivative or derivative security
over a month ago at www.macroaxis.com 
Acquisition by Brett Pletcher of tradable shares of Gilead Sciences subject to Rule 16b-3
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3
over a month ago at http://seekingalpha.com 
Gilead Sciences, Inc. CEO John Milligan at the Morgan Stanley 16th Annual Global Healthcare Conference ...
seekingalpha News
Seeking AlphaAmerican Century Companies Inc. Has 212.04 Million Holdings in Gilead Sciences, Inc. Fairfield CurrentAmerican International Group Inc. Has 447.90 Million Holdings in Gilead Sciences, Inc. Marea Informative Full coverage
over two months ago at www.macroaxis.com 
Exercise or conversion by Kevin Young of 13207 shares of Gilead Sciences subject to Rule 16b-3
Macroaxis News
Filed transaction by Gilead Sciences Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three months ago at http://www.nasdaq.com 
Biotech Stock Roundup PBYI Soars, MACK Crashes, GILDs Biktarvy Gets EC Nod
nasdaq News
NasdaqFull coverage

Latest Stories

Recently Published Stories

Compare Gilead Sciences

Compare Gilead Sciences To Peers

Total Asset

Total Asset Comparative Analysis

  Total Asset 
      Gilead Sciences Comparables 
Gilead Sciences is currently under evaluation in total asset category among related companies. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Please also check Gilead Sciences Hype Analysis, Gilead Sciences Correlation and Gilead Sciences Performance. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.
Search macroaxis.com